Opko Health, Inc. (OPK): Modelo de negócios Canvas [Jan-2025 Atualizado]

No cenário dinâmico da inovação em saúde, a Opko Health, Inc. (OPK) surge como uma força transformadora, navegando estrategicamente nas complexas interseções de diagnóstico, produtos farmacêuticos e medicina personalizada. Esta empresa de ponta criou meticulosamente um modelo de negócios que não apenas impulsiona o avanço tecnológico, mas também redefine como as soluções médicas são desenvolvidas, entregues e integradas ao ecossistema global de saúde. Ao alavancar parcerias estratégicas, pesquisa inovadora e uma abordagem abrangente da tecnologia médica, a OPKO Health demonstra um compromisso extraordinário em revolucionar o atendimento ao paciente e o diagnóstico médico.

Opko Health, Inc. (OPK) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com empresas farmacêuticas

A OPKO Health estabeleceu parcerias estratégicas com as seguintes empresas farmacêuticas:

Empresa parceira	Foco de colaboração	Ano estabelecido
Pfizer Inc.	Desenvolvimento de hormônios do crescimento de Somatrogon	2019
Tesaro (adquirido pela GSK)	Colaboração de Tecnologia de Diagnóstico	2017

Parcerias de pesquisa com instituições acadêmicas e médicas

O OPKO Health mantém colaborações de pesquisa com:

• Faculdade de Medicina da Universidade de Miami Miller
• Escola de Medicina de Harvard
• Clínica Mayo

Acordos de distribuição com provedores globais de saúde

As principais parcerias de distribuição incluem:

Prestador de cuidados de saúde	Cobertura geográfica	Foco do produto
Cardinal Health	Estados Unidos	Distribuição de equipamentos de diagnóstico
McKesson Corporation	América do Norte	Distribuição farmacêutica

Acordos de licenciamento para tecnologias de diagnóstico

A Opko Health garantiu acordos de licenciamento com:

• Laboratórios de BioReference
• GeDX (Tecnologias de Testes Genéticos)

Joint ventures em biotecnologia e pesquisa médica

Investimentos atuais de joint venture:

Parceiro de joint venture	Valor do investimento	Área de pesquisa
Israel Chemicals Ltd.	US $ 12,5 milhões	Diagnóstico molecular
Diagnóstico da ARIOSA	US $ 35 milhões	Teste genético pré -natal

Opko Health, Inc. (OPK) - Modelo de negócios: Atividades -chave

Pesquisa e Desenvolvimento Farmacêutico

Despesas anuais de P&D em 2022: US $ 162,1 milhões

Áreas de foco em P&D	Alocação de investimento
Desenvolvimento de Biológicos	42% do orçamento de P&D
Tecnologias de diagnóstico	33% do orçamento de P&D
Terapias de doenças raras	25% do orçamento de P&D

Criação de teste de diagnóstico e inovação

Portfólio de testes de diagnóstico total: 17 testes proprietários

• Plataforma de diagnóstico molecular 4D
• Tecnologias de testes genéticos
• Soluções de diagnóstico de medicina de precisão

Fabricação de produtos biofarmacêuticos

Instalações de fabricação: 3 locais globais

Localização	Capacidade de fabricação
Miami, Flórida	Produção Primária Biológica
Israel	Fabricação farmacêutica especializada
Porto Rico	Instalação de produção secundária

Ensaios clínicos e testes médicos

Ensaios clínicos ativos em 2022: 12 estudos em andamento

• Ensaios de oncologia: 4 estudos
• Ensaios de endocrinologia: 3 estudos
• Ensaios de doenças raras: 5 estudos

Comercialização de tecnologias de saúde

Receita de tecnologias comercializadas em 2022: US $ 1,47 bilhão

Segmento de tecnologia	Receita comercial
Soluções de diagnóstico	US $ 487 milhões
Produtos farmacêuticos	US $ 683 milhões
Terapêutica especializada	US $ 300 milhões

Opko Health, Inc. (OPK) - Modelo de negócios: Recursos -chave

Tecnologias de diagnóstico e farmacêuticos proprietários

O OPKO Health mantém um portfólio de 588 patentes a partir de 2023, com os principais ativos tecnológicos, incluindo:

• Teste de diagnóstico de câncer de próstata 4KSCore
• Terapia hormonal de crescimento de ação prolongada
• Rayaldee para doença renal crônica

Instalações de pesquisa e desenvolvimento

Localização	Foco na pesquisa	Tamanho da instalação
Miami, FL	Desenvolvimento farmacêutico	45.000 pés quadrados.
San Diego, CA.	Tecnologias de diagnóstico	32.000 pés quadrados.

Portfólio de propriedade intelectual

Contagem total de patentes: 588 patentes

• Patentes de Tecnologia de Diagnóstico: 276
• Patentes de tecnologia farmacêutica: 312

Equipe de pesquisa científica e médica qualificada

Categoria de funcionários	Número	Percentagem
Cientistas de pesquisa	187	42%
Pesquisadores médicos	129	29%
Especialistas clínicos	130	29%

Equipamento avançado de laboratório e teste

Tipo de equipamento	Quantidade	Valor total
Sistemas de cromatografia líquida de alta eficiência (HPLC)	24	US $ 3,6 milhões
Espectrômetros de massa	18	US $ 4,5 milhões
Máquinas de sequenciamento genético	12	US $ 7,2 milhões

Opko Health, Inc. (OPK) - Modelo de negócios: proposições de valor

Soluções de Diagnóstico Inovadoras para Precisão Healthcare

O segmento de diagnóstico da Opko Health gera US $ 295,2 milhões em receita anual (2022 Relatório Financeiro). A Divisão de Laboratórios de BioReference da Companhia processa aproximadamente 80 milhões de testes de laboratório anualmente.

Tecnologia de diagnóstico	Volume de teste anual	Penetração de mercado
Teste genético de precisão	1,2 milhão de testes	14% de participação de mercado
Diagnóstico molecular	3,5 milhões de testes	9% de participação de mercado

Tecnologias abrangentes de testes médicos

A OPKO Health investe US $ 127,6 milhões anualmente em P&D para tecnologias de testes médicos.

• Plataformas de triagem molecular 4D
• Sistemas de análise genômica avançada
• Soluções integradas de fluxo de trabalho de diagnóstico

Tratamentos farmacêuticos avançados

Receita do segmento farmacêutico: US $ 412,7 milhões (2022 ano fiscal).

Produto farmacêutico	Vendas anuais	Segmento de mercado
Rayaldee (tratamento de vitamina D)	US $ 63,4 milhões	Doença renal crônica
Tratamentos imunológicos de argx	US $ 89,6 milhões	Distúrbios autoimunes

Diagnósticos de saúde econômicos

Redução de custos médios para testes de diagnóstico: 22% em comparação com os preços padrão da indústria.

• Plataformas de teste automatizadas
• Recursos de processamento em massa
• Infraestrutura laboratorial eficiente

Estratégias personalizadas de triagem médica e intervenção

Receita de triagem personalizada: US $ 176,3 milhões (relatório financeiro de 2022).

Categoria de triagem	Exibições anuais	Segmentos de pacientes
Avaliação de risco genético	245.000 pacientes	Oncologia, condições hereditárias
Mapeamento de intervenção de precisão	167.000 pacientes	Gerenciamento de doenças crônicas

Opko Health, Inc. (OPK) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento profissional médico direto

A OPKO Health mantém o envolvimento direto com os profissionais médicos por meio de canais de comunicação direcionados:

Método de engajamento	Volume anual de interação
Apresentações da conferência médica	37 Conferências científicas em 2023
Série de webinar profissional	24 webinars médicos especializados
Contatos de representação de vendas diretas	168 representantes de vendas dedicados

Suporte técnico para profissionais de saúde

A infraestrutura de suporte técnico para prestadores de serviços de saúde inclui:

• 24/7 de suporte clínico
• Equipe de suporte técnico dedicado de 42 especialistas
• Base de conhecimento on -line com 1.287 documentos de recursos médicos

Plataformas de suporte de pacientes online

Recurso da plataforma	Métricas
Usuários do portal de pacientes	87.643 usuários registrados
Recursos de saúde digital	463 documentos de informações médicas online
Downloads de aplicativos móveis	56.291 downloads totais

Comunicação contínua de pesquisa médica

Os canais de comunicação de pesquisa incluem:

• Newsletters trimestrais de atualização de pesquisa
• 12 Documentos de pesquisa clínica publicados em 2023
• Participação em 29 colaborações internacionais de pesquisa médica

Serviços personalizados de consulta de saúde

Tipo de consulta	Volume anual de serviço
Consultas de telessaúde	14.672 consultas virtuais
Aconselhamento genético especializado	3.246 consultas personalizadas
Orientação de medicina de precisão	2.893 consultas individuais

Opko Health, Inc. (OPK) - Modelo de Negócios: Canais

Vendas diretas para instituições de saúde

A OPKO Health emprega uma força de vendas direta direcionada às instituições de saúde. A partir de 2023, a empresa manteve uma equipe de vendas de aproximadamente 150 representantes especializados em linhas de produtos farmacêuticos e de diagnóstico.

Tipo de canal de vendas	Número de representantes	Segmentos de assistência médica -alvo
Vendas farmacêuticas	85	Hospitais, clínicas
Vendas de diagnóstico	65	Redes de laboratório, instituições de pesquisa

Plataformas médicas online

A OPKO Health aproveita as plataformas digitais para distribuição de produtos e disseminação de informações médicas.

• Portal médico on -line com 45.000 profissionais de saúde registrados
• Catálogo de produtos digitais com rastreamento de inventário em tempo real
• Plataforma de integração de telemedicina

Conferências e Exposições Médicas

A OPKO Health participa de aproximadamente 22 conferências médicas internacionais anualmente, representando um investimento de US $ 1,2 milhão em participação e marketing da conferência.

Redes de distribuidores farmacêuticos

Tipo de distribuidor	Número de parceiros	Cobertura geográfica
Distribuidores farmacêuticos nacionais	12	Estados Unidos
Distribuidores internacionais	8	Europa, América Latina

Canais de marketing digital e comunicação médica

Orçamento de marketing digital para 2023: US $ 3,7 milhões

• Engajamento de mídia social: 125.000 seguidores profissionais de saúde
• Banco de dados de marketing por email: 87.000 contatos
• Série de seminários on -line atingindo 15.000 profissionais médicos trimestralmente

Opko Health, Inc. (OPK) - Modelo de negócios: segmentos de clientes

Provedores de saúde

A OPKO Health atende a aproximadamente 12.500 prestadores de serviços de saúde nos Estados Unidos a partir de 2023.

Tipo de provedor	Número de clientes	Penetração de mercado
Médicos de cuidados primários	6,800	54.4%
Especialistas	4,200	33.6%
Centros de atendimento urgente	1,500	12%

Hospitais e centros médicos

A OPKO Health atende a 782 hospitais e centros médicos em todo o país em 2023.

• Centros Médicos Acadêmicos: 124
• Hospitais comunitários: 458
• Hospitais Especiais: 200

Instituições de pesquisa

A Opko Health colabora com 215 instituições de pesquisa em todo o mundo.

Tipo de instituição	Número de parcerias
Centros de Pesquisa Universitária	142
Institutos de Pesquisa Privada	73

Empresas farmacêuticas

A OPKO Health possui parcerias ativas com 38 empresas farmacêuticas em 2023.

• As 20 principais empresas farmacêuticas globais: 22
• Empresas farmacêuticas de tamanho médio: 16

Pacientes individuais

A OPKO Health atende a aproximadamente 1,2 milhão de pacientes individuais por meio de serviços diagnósticos e farmacêuticos.

Segmento de pacientes	Número de pacientes
Teste de diagnóstico	650,000
Tratamentos farmacêuticos	550,000

Opko Health, Inc. (OPK) - Modelo de negócios: estrutura de custos

Extensas despesas de pesquisa e desenvolvimento

A OPKO Health, Inc. registrou despesas de P&D de US $ 171,5 milhões no ano fiscal de 2022.

Ano	Despesas de P&D	Porcentagem de receita
2022	US $ 171,5 milhões	33.2%
2021	US $ 159,3 milhões	31.8%

Investimentos de ensaios clínicos

Os custos de ensaios clínicos para a OPKO Health em 2022 foram de aproximadamente US $ 82,3 milhões, com foco nas áreas terapêuticas -chave.

• Ensaios clínicos biofarmacêuticos: US $ 52,6 milhões
• Pesquisa clínica de diagnóstico: US $ 29,7 milhões

Custos de fabricação e produção

As despesas totais de fabricação de 2022 atingiram US $ 214,6 milhões.

Categoria de fabricação	Custo
Produção farmacêutica	US $ 138,2 milhões
Produção de equipamentos de diagnóstico	US $ 76,4 milhões

Despesas de marketing e vendas

As despesas de marketing e vendas da OPKO Health em 2022 totalizaram US $ 97,4 milhões.

• Marketing farmacêutico: US $ 62,3 milhões
• Marketing de diagnóstico: US $ 35,1 milhões

Despesas regulatórias de conformidade e certificação

Os custos de conformidade regulatórios para 2022 foram de US $ 24,7 milhões.

Categoria de conformidade	Despesa
Conformidade da FDA	US $ 15,6 milhões
Certificações regulatórias internacionais	US $ 9,1 milhões

Opko Health, Inc. (OPK) - Modelo de negócios: fluxos de receita

Vendas de teste de diagnóstico

No ano fiscal de 2022, a OPKO Health gerou US $ 320,4 milhões em vendas de testes de diagnóstico por meio de seu segmento de Laboratórios de BioReference.

Categoria de teste de diagnóstico	Receita (2022)
Teste Covid-19	US $ 87,6 milhões
Teste clínico de rotina	US $ 157,2 milhões
Testes de diagnóstico especializados	US $ 75,6 milhões

Receitas de produtos farmacêuticos

O segmento farmacêutico da Opko Health gerou US $ 184,9 milhões em receitas de produtos em 2022.

• Rayaldee (tratamento de vitamina D): US $ 42,3 milhões
• Varubi (medicamento anti-náusea): US $ 12,7 milhões
• Outros produtos farmacêuticos: US $ 129,9 milhões

Taxas de licenciamento e transferência de tecnologia

A OPKO Health registrou US $ 23,5 milhões em receitas de licenciamento e transferência de tecnologia em 2022.

Parceiro de licenciamento	Área de tecnologia	Valor da taxa
Pfizer	Somatrogon (hormônio do crescimento)	US $ 15,2 milhões
Outros parceiros farmacêuticos	Várias plataformas de biotecnologia	US $ 8,3 milhões

Subsídios de pesquisa e colaborações

A Opko Health recebeu US $ 7,8 milhões em subsídios de pesquisa e financiamento colaborativo em 2022.

Serviços de consulta de tecnologia médica

Os serviços de consulta geraram US $ 5,6 milhões em receita adicional para a OPKO Health em 2022.

Receita total para 2022: US $ 542,2 milhões

OPKO Health, Inc. (OPK) - Canvas Business Model: Value Propositions

The value propositions for OPKO Health, Inc. (OPK) as of late 2025 center on specialized diagnostics and a focused, high-potential pharmaceutical pipeline, often structured through partnerships to mitigate risk.

Next-generation, long-acting human growth hormone therapy (NGENLA)

This value is delivered through a royalty arrangement with Pfizer Inc. (PFE), which handles ownership and distribution. The financial return is realized via gross profit sharing, which has shown variability:

• OPKO Health estimated annual gross profit share revenue for NGENLA between $28 million and $35 million for the full year 2025.
• Gross profit share payments totaled $6.1 million in the second quarter of 2025, down from $6.3 million in the second quarter of 2024.
• Gross profit share payments increased to $8.8 million in the third quarter of 2025, up from $7 million in the third quarter of 2024.
• The company earned $10.6 million from NGENLA profit share in the first six months of 2025.
• Analyst guidance for 2026 suggested a year-over-year flat expectation of $32-35 million.

Improved risk assessment for aggressive prostate cancer (4Kscore Test)

The value here is enhanced diagnostic accuracy, supported by regulatory milestones and market relevance:

• The U.S. Food and Drug Administration (FDA) approved a supplemental application in the second quarter of 2025, allowing the 4Kscore® Test to be performed without digital rectal examination (DRE) information.
• Clinical studies concluded the test is reliable with greater than 96% sensitivity and accuracy (n=937).
• The 4Kscore® Test franchise was part of the core clinical testing services that represented approximately $300 million in revenue for 2024.

Treatment for Secondary Hyperparathyroidism (SHPT) in chronic kidney disease patients (Rayaldee)

Rayaldee provides a treatment option for SHPT patients, with product sales showing modest movement in 2025:

Period	Rayaldee Net Sales (Millions USD)
Q1 2025	$6.3 million
Q2 2025	$7.2 million
Q3 2025	$7.5 million
Full Year 2023	$31.0 million

The third quarter of 2025 sales of $7.5 million represented a 29.3% increase from the prior-year period.

Streamlined, focused core clinical testing services in the New York/New Jersey region

Following the sale of oncology assets to Labcorp, the remaining diagnostics business is focused on core services, including the New York/New Jersey region operations:

• The core clinical testing services in the New York and New Jersey region represented approximately $300 million in revenue for 2024.
• Management provided an outlook that the remaining annual revenue from this focused business is approximately $300 million.
• Full-year 2025 guidance for total Revenue from Services was set between $400 million and $500 million, which includes $95 million to $105 million from the assets being sold.
• Third quarter 2025 Diagnostics revenue from services was $95.2 million.

Potential for novel oral treatments for obesity and metabolic disorders (OPK-88006 pipeline)

This represents a high-potential value stream via a partnership to develop a first-in-class oral therapy:

• OPK-88006 is a dual agonist of the GLP-1 and glucagon receptors, intended as a once-daily tablet.
• OPKO Health and Entera Bio expect to file an Investigational New Drug (IND) application later in 2025.
• OPKO Health will hold a 60% ownership interest and be responsible for 60% of the development costs in the collaboration.
• OPKO purchased approximately 3.7 million ordinary shares of Entera at $2.17 per share.

OPKO Health, Inc. (OPK) - Canvas Business Model: Customer Relationships

You're looking at how OPKO Health, Inc. manages its connections with the various groups it serves-from the doctors prescribing its drugs to the patients using its lab services. It's a mix of direct sales, high-level partnerships, and digital self-service.

Dedicated personal selling via field-based nephrology sales representatives for Rayaldee

For Rayaldee, the relationship is definitely hands-on, relying on field-based nephrology sales reps to drive adoption with specialists. This direct engagement is key for a specialty pharmaceutical product. We see the results of this effort reflected in the quarterly sales figures for the drug. For instance, Rayaldee sales hit $7.5 million in the third quarter of 2025, which was an increase from the $5.8 million seen in the third quarter of 2024. However, the first quarter of 2025 saw Rayaldee sales at $6.3 million, a slight dip from the $6.9 million in the first quarter of 2024, and Q2 2025 sales were flat year-over-year at $7.2 million. This fluctuation shows the ongoing effort required in this relationship channel.

Co-development and licensing management with large pharmaceutical partners

Managing relationships with big pharma partners is crucial, especially for monetizing the pipeline through licensing. Take NGENLA, for example, which is on a royalty arrangement with Pfizer Inc. Management estimated full-year 2025 royalty revenue from this to be between $28 million and $35 million, a potential step up from the prior year's profit-share revenue of $28.3 million. The second quarter of 2025 saw royalty payments of $6.1 million. Then there's the ModeX collaboration with Regeneron Pharmaceuticals. This relationship is structured for massive upside, with OPKO Health, Inc. entitled to an upfront payment and potential milestone payments exceeding $200 million for each program, pushing the overall collaboration value potentially past $1 billion if multiple products succeed. Regeneron handles all the development and commercialization costs, which is a very strong customer/partner dynamic for OPKO Health, Inc.

Self-service digital Patient Portal for lab results and billing (BioReference)

For the diagnostics side, which is now more focused after the Labcorp asset sale, the relationship is heavily digitized through the BioReference Patient Portal. This is a self-service channel where patients can access their most recent laboratory reports, review past results, pay their bill, and update insurance information all online. Following the sale of the oncology and related clinical testing assets, the remaining BioReference core clinical testing services, including the 4Kscore Test franchise, continue to rely on this portal for patient interaction. While specific user numbers aren't public, the portal's existence supports a high-volume service model.

Shared decision-making support tools for physicians and patients (4Kscore Test)

The 4Kscore Test is a prime example of a tool designed to foster shared decision-making. This blood test, which combines four biomarkers with clinical factors, provides a numerical value to assess the risk of aggressive prostate cancer before a biopsy. The 4Kscore Test franchise itself represented approximately $300 million in revenue for BioReference in 2024. Historically, the test has been utilized by over 7,700 health care providers, including about 4,200 urologists, as of a 2021 report. OPKO Health, Inc. confirmed that BioReference will continue to offer this comprehensive Urology diagnostic service nationwide, meaning this decision-support relationship remains a core offering.

Customer Service teams available 24/7 for healthcare provider inquiries

For healthcare providers needing support with BioReference services, there are dedicated contact channels. While the outline specifies 24/7 availability, the publicly available contact information lists specific phone numbers for billing inquiries (e.g., 833-469-5227) and patient portal support (e.g., 1-888-279-0967, M-F 9AM-5PM ET for login issues), alongside general corporate contact numbers. The existence of these dedicated lines shows a commitment to addressing provider needs, which is vital for maintaining lab service relationships.

Here's a quick look at some of the key financial and statistical touchpoints related to these customer and partner relationships as of late 2025:

Relationship/Product Metric	Latest Reported Value (2025)	Context/Period
Rayaldee Product Revenue	$7.5 million	Q3 2025
Rayaldee Product Revenue	$6.3 million	Q1 2025
NGENLA Royalty Revenue Estimate (Low End)	$28 million	Full Year 2025 Guidance
NGENLA Royalty Payment Received	$6.1 million	Q2 2025
ModeX/Regeneron Potential Milestone Payments (Per Program)	Exceeding $200 million	Per Program
4Kscore Test Franchise Revenue	Approx. $300 million	2024 Annualized Figure
BioReference Headcount (Pre-Transaction Target)	1,450-1,500	Expected by Q4 post-transaction

Finance: draft 13-week cash view by Friday.

OPKO Health, Inc. (OPK) - Canvas Business Model: Channels

You're looking at how OPKO Health, Inc. gets its products and services into the hands of patients and providers as of late 2025. It's a mix of relying on big pharma muscle, a focused internal team, and established lab infrastructure.

Global Distribution Network Managed by Partners

For NGENLA, the growth hormone therapy, distribution is handled entirely by the partner, Pfizer. This channel provides global reach, with NGENLA now approved in over 40 markets worldwide. This partnership structure directly translates into royalty/profit share revenue for OPKO Health, Inc. For the third quarter of 2025, the gross profit share payments for NGENLA hit $8.8 million. Looking ahead, the guidance for NGENLA sales in 2026 is set between $32 million and $35 million.

Direct Sales Force Targeting Specialists in the U.S.

For its own pharmaceutical product, Rayaldee, OPKO Health, Inc. relies on a dedicated, specialized sales force within the U.S. targeting nephrologists. While the specific 2025 headcount isn't public, the company previously had plans to expand its field-based nephrology sales representatives to 70. This team supports the commercialization efforts for Rayaldee, which generated $7.5 million in revenue in the third quarter of 2025.

• NGENLA distribution is managed by Pfizer globally.
• Rayaldee commercialization is supported by a specialized U.S. sales team.
• Rayaldee is marketed in the U.S., Germany, Switzerland and Denmark.

BioReference Patient Service Centers and Mobile Phlebotomy Services

The diagnostics arm, primarily through BioReference Laboratories, utilizes a massive physical footprint for sample collection. BioReference Laboratories services approximately 11 million patients annually. Even after the sale of certain oncology assets, the core clinical testing operations in New York and New Jersey, which include some patient service centers (PSCs), represented approximately $300 million in revenue for 2024. The mobile component is supported by a logistics fleet of over 475 cars, driving over 17 million miles annually to support sample collection and delivery.

Specialty Pharmacies and Pharmaceutical Wholesalers for Rayaldee Distribution

Rayaldee, the treatment for secondary hyperparathyroidism, moves through traditional pharmaceutical supply channels. Shipments commence to distributors, making the product available nationwide at retail pharmacies. This channel is critical for reaching the adult patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency who are not on dialysis.

Provider Login Portals for Secure, 24/7 Access to Test Data and EHR Integration

For its diagnostic services, OPKO Health, Inc. provides digital access points for ordering and results retrieval. The company maintains a Provider Login portal, which is the mechanism for healthcare professionals to get secure, 24/7 access to test data. This digital channel is key for integrating results into the provider workflow, especially for tests like the 4Kscore® Test, which is reliable with over 96% sensitivity and accuracy in assessing aggressive prostate cancer probability.

Here's a quick look at the revenue and scale associated with these channels as of late 2025 data:

Channel/Product Metric	Latest Reported Value/Amount	Period/Context
NGENLA Gross Profit Share Revenue	$8.8 million	Q3 2025
NGENLA Global Approvals	Over 40 markets	Late 2025
Rayaldee Revenue	$7.5 million	Q3 2025
BioReference Annual Patient Volume	Approximately 11 million	Latest Data
BioReference NY/NJ Core Revenue	Approximately $300 million	2024
4Kscore Test Accuracy	Over 96%	Latest Data

Finance: review Q4 2025 revenue projections based on NGENLA profit share run rate by next Tuesday.

OPKO Health, Inc. (OPK) - Canvas Business Model: Customer Segments

Global pharmaceutical companies seeking co-development and licensing deals

• ModeX collaboration potential value exceeds $1 billion upon success of multiple products.
• ModeX eligible for tiered royalties on global net sales, up to low double digits at the highest tier.
• Ongoing Phase 1 clinical trial for Epstein-Barr virus vaccine with Merck.
• Collaboration with Entera Bio for oral tablet development.

Patients with pediatric growth hormone deficiency (NGENLA)

Metric	Q3 2025 Amount	Q2 2025 Amount	Q1 2025 Amount	2024 Amount
Gross Profit Share Revenue (USD)	$8.8 million	$6.1 million	$4.5 million	$28.3 million (Profit-share revenue)
Estimated Full Year 2025 Profit Share (USD)	$28 million to $35 million (Estimate)
2026 Guidance Range (USD)	$32 million to $35 million (Guidance)

Adult patients with Stage 3 or 4 Chronic Kidney Disease and SHPT (Rayaldee)

Metric	Q3 2025 Revenue (USD)	Q2 2025 Revenue (USD)	Q1 2025 Revenue (USD)
Rayaldee Sales	$7.5 million	$7.2 million	$6.3 million

Urologists and Primary Care Physicians utilizing the 4Kscore Test

• The 4Kscore Test franchise represented approximately $300 million in revenue for 2024.
• Test volume increased year-over-year by approximately 12% in Q2 2025.
• Over 90% of PSA screening tests are performed by primary care providers, potential users.
• FDA approved supplemental application in July 2025 enabling performance without digital rectal examination (DRE) information.

Healthcare providers and patients in the New York/New Jersey region for core clinical testing

Metric	Q3 2025 Revenue (USD)	Q2 2025 Revenue (USD)	Q1 2025 Revenue (USD)
Diagnostics Segment Revenue from Services	$95.2 million	$101.1 million	$102.8 million
Estimated Annualized Revenue (Remaining Business)	Approximately $300 million annually

The remaining BioReference business is expected to reach profitability this year. Finance: draft 13-week cash view by Friday.

OPKO Health, Inc. (OPK) - Canvas Business Model: Cost Structure

You're looking at the expense side of OPKO Health, Inc.'s operations as of late 2025, which is heavily influenced by its dual focus on pharmaceuticals in development and a streamlined diagnostics business. Here's a breakdown of the major cost drivers based on the third quarter of 2025 results.

The company's operating expenses reflect significant investment in its pipeline alongside cost management in its lab services arm. Research and development (R&D) expenses, totaling $30.1 million in Q3 2025, represent a key outlay for future growth potential. This figure is up 4.5% year over year, driven largely by activities within the ModeX development programs.

Selling, General, and Administrative (SG&A) expenses were reported at $53.8 million for the third quarter of 2025, showing a substantial decline of 45.2% compared to the prior-year quarter, which reflects the impact of strategic realignment and asset sales.

The overall cost structure is detailed in the table below, incorporating the reported revenue and profit figures to derive the cost of revenue components for both segments.

Cost Category	Q3 2025 Amount (Millions USD)	Notes
Research and Development (R&D) Expenses	$30.1	Primarily for pharmaceutical pipeline advancement, including ModeX programs.
Selling, General, and Administrative (SG&A) Expenses	$53.8	Declined 45.2% year over year due to cost containment.
Cost of Revenue (Calculated)	Approx. $101.8	Calculated as Total Revenue ($151.7M) less Gross Profit ($49.9M).
Nonrecurring Costs (Severance)	Approx. $4.2	Expected nonrecurring costs for severance during Q3 2025.

Cost of revenue is a major component, reflecting the operational expenses tied directly to generating the $95.2 million in diagnostic services revenue and $37.7 million in pharmaceutical product revenue for the quarter. The decrease in diagnostics cost of revenue is directly linked to the sale of certain BioReference assets, which saw cost and expenses drop significantly compared to the prior year.

Clinical trial costs are embedded within the R&D spend, specifically supporting pipeline candidates. You see activity across several fronts:

• The Merck and ModeX collaboration on the Epstein-Barr virus vaccine candidate, which entered Phase 1 study in early 2025.
• Advancement of ModeX tetraspecific antibody candidates, with some expected to enter human trials in late 2025 or early 2026.
• Development costs for the oral GLP-1/glucagon tablet candidate with Entera Bio, where OPKO Health is responsible for 60% of development costs.

Restructuring efforts have yielded significant expense reductions, particularly within the Diagnostics business following the Labcorp transaction. While the sale itself generated gains, the underlying cost structure was targeted for efficiency. Management has noted that cost-reduction initiatives were in place, with annualized savings of over $25 million expected from prior restructuring efforts. Furthermore, the company recorded approximately $4.2 million in expected nonrecurring severance costs in Q3 2025 alone.

Finance: draft 13-week cash view by Friday.

OPKO Health, Inc. (OPK) - Canvas Business Model: Revenue Streams

You're looking at how OPKO Health, Inc. (OPK) brings in cash as of late 2025. The revenue picture is clearly segmented across its Diagnostics and Pharmaceuticals divisions, with a notable contribution from non-core activities like IP monetization. This mix shows a company balancing service-based lab revenue with product sales and strategic financial events.

Here is a look at the key revenue components from the third quarter of 2025, which gives you a snapshot of the current operational flow:

Revenue Source	Q3 2025 Amount
Revenue from services (Diagnostics)	$95.2 million
Revenue from product sales (Pharmaceuticals)	$37.7 million
Revenue from the transfer of intellectual property and other	$18.8 million
Gross profit share payments from partners for NGENLA	$8.8 million

The Diagnostics segment, driven by BioReference Health, remains the largest top-line contributor, though it has been streamlined following asset sales. The Pharmaceutical revenue stream is more diverse than just product sales, so you need to watch the non-product elements closely. These are the specific revenue drivers you should be tracking:

• Revenue from services (Diagnostics), which was $95.2 million in Q3 2025.
• Revenue from product sales (Pharmaceuticals), totaling $37.7 million in Q3 2025.
• Revenue from the transfer of intellectual property and other, which was $18.8 million in Q3 2025.
• Gross profit share payments from partners for NGENLA, totaling $8.8 million in Q3 2025.

To be fair, the IP and other category is where you see the impact of deals like the one with Regeneron, plus royalties. Looking ahead, the full-year 2025 total revenue guidance is projected to be between $640 million and $660 million, which suggests the fourth quarter needs to perform solidly to hit that range after the Q3 results. Finance: draft 13-week cash view by Friday.